Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. has received approval in Germany for an international multi-center phase 3 clinical trial of its HLX22 monoclonal antibody in combination with other therapies for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s efforts to expand its clinical trials across multiple regions, potentially enhancing its market positioning and offering new treatment options for patients with these types of cancer.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative monoclonal antibodies for the treatment of various cancers, including gastric and breast cancer. The company is known for its self-developed products such as HLX22, which targets HER2-positive cancers.
YTD Price Performance: 59.70%
Average Trading Volume: 1,632,407
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.57B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.